Breaking News Instant updates and real-time market news.

ABMD

Abiomed

$394.49

0.04 (0.01%)

, WYN

Wyndham

$107.98

-0.58 (-0.53%)

17:21
05/25/18
05/25
17:21
05/25/18
17:21

ABIOMED to replace Wyndham in the S&P 500 at open on May 31st

ABMD

Abiomed

$394.49

0.04 (0.01%)

WYN

Wyndham

$107.98

-0.58 (-0.53%)

  • 30

    May

  • 05

    Jun

  • 12

    Jun

ABMD Abiomed
$394.49

0.04 (0.01%)

02/22/18
PIPR
02/22/18
NO CHANGE
Target $300
PIPR
Overweight
Piper sees 'so much to like' at Abiomed, recommends buying shares
After hosting investor meetings with Abiomed management, Piper Jaffray analyst Matt O'Brien says "there is so much to like here." Management noted that the label expansions from last week were likely to expand the shock patient population by 20%-25%, O'Brien tells investors in a research note. He sees "significant room for growth" from Impella and keeps an Overweight rating on Abiomed shares with a $300 price target. The analyst continues to encourage investors to start or build positions.
04/04/18
GSCO
04/04/18
INITIATION
Target $332
GSCO
Buy
Abiomed initiated with a Buy at Goldman Sachs
Goldman Sachs analyst Issac Ro started Abiomed with a Buy rating and $332 price target.
04/25/18
PIPR
04/25/18
NO CHANGE
PIPR
Overweight
Piper says IPPS rates appear negative, but are really neutral for Abiomed
After Abiomed issued an 8k discussing the Centers for Medicare and Medicaid Services' proposed Inpatient Prospective Payment System, or IPPS, rates for Impella, Piper Jaffray analyst Matt O'Brien said the rates look negative "at first blush." However, when considering that very few Impella cases are billed to the DRG code for which the CMS proposed a cut of 24%, he said he views the proposed IPPS as "fairly neutral" for Abiomed. Adding that the code where most Impella cases are performed is proposed to be up about 3% in the current rule, O'Brien said he would take advantage of any weakness to start or build Abiomed positions. He keeps an Overweight rating on the shares.
05/03/18
PIPR
05/03/18
NO CHANGE
Target $360
PIPR
Overweight
Abiomed price target raised to $360 from $300 at Piper Jaffray
Piper Jaffray analyst Matt O'Brien raised his price target for Abiomed to $360 saying this morning's Q4 results easily beat his estimates. The momentum in using Impella to treat patients "remains strong" and there are new products and geographies that should continue to drive sales, O'Brien tells investors in a post-earnings research note. The analyst, while admitting the valuation is "hefty," reiterates an Overweight rating on Abiomed. He continues to encourage investors to own the name.
WYN Wyndham
$107.98

-0.58 (-0.53%)

03/23/18
STFL
03/23/18
NO CHANGE
Target $135
STFL
Buy
Wyndham shares have more room to run, says Stifel at Stifel
Stifel analyst Simon Yarmak took a deep dive into Wyndham Worldwide's Form 10 for the previously announced spin-off of Wyndham Hotels & Resorts, which is expected in Q2. In a research note to investors, Yarmak, who has a Buy rating and $135 price target on shares, said shares have had a "good" run, with shares up 21.3% vs. the S&P since the spin was announced in August, and sees more room for shares to run. He sees upside heading into the spinoff.
04/02/18
OPCO
04/02/18
INITIATION
Target $135
OPCO
Outperform
Wyndham initiated with an Outperform at Oppenheimer
Oppenheimer analyst Ian Zaffino started Wyndham Worldwide (WYN) with an Outperform rating and $135 price target, calling the company the leader in the economy/upper-economy hotel space and saying he believes the planned acquisition of La Quinta (LQ) will also make it the leader in the premier midscale segment.
05/07/18
STFL
05/07/18
NO CHANGE
Target $131
STFL
Buy
Wyndham selloff after earnings overdone, says Stifel
Stifel analyst Simon Yarmak said Wyndham's (WYN) Q1 earnings release was a headline beat and he viewed the incremental information as largely positive, stating that he sees the selloff since as being overdone and recommends buying the shares ahead of the spinoff. While the Marriott Vacations (VAC) and ILG (ILG) deal may have disappointed some investors with respect to synergies, the acquisition price should have a positive read-through to Wyndham, added Yarmak. He lowered his price target on Wyndham to $131 from $135 and keeps a Buy rating on the shares.
05/18/18
FBCO
05/18/18
INITIATION
Target $116
FBCO
Neutral
Wyndham initiated with a Neutral at Credit Suisse
Credit Suisse analyst Cameron McKnight started Wyndham with a Neutral rating and $116 price target, stating in a note to investors sent earlier this morning that while he is positive on the timeshare space, he sees a mix of fundamental positives and challenges for Wyndham, the largest timeshare company which will shortly spin off its hotel business.

TODAY'S FREE FLY STORIES

ATHN

Athenahealth

$133.86

-9.395 (-6.56%)

10:13
09/18/18
09/18
10:13
09/18/18
10:13
Periodicals
Athenahealth extends bid date to accommodate new possible bidder, CNBC reports »

CNBC's David Faber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:10
09/18/18
09/18
10:10
09/18/18
10:10
General news
Housing Market Index data reported »

September Housing Market…

TLRY

Tilray

$135.75

15.55 (12.94%)

10:10
09/18/18
09/18
10:10
09/18/18
10:10
Options
Tilray options active with shares high as a kite »

Tilray options active…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MDT

Medtronic

$96.09

0.09 (0.09%)

10:05
09/18/18
09/18
10:05
09/18/18
10:05
Hot Stocks
Medtronic announces FDA approval for revised TAVR labeling, begins study »

Medtronic announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Oct

TLRY

Tilray

$132.62

12.42 (10.33%)

10:03
09/18/18
09/18
10:03
09/18/18
10:03
Periodicals
Citron Research calls Tilray news 'promotional and misleading' »

Citron Research just…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BBT

BB&T

$50.16

-0.08 (-0.16%)

10:01
09/18/18
09/18
10:01
09/18/18
10:01
Earnings
BB&T announces $5M investment in Enigma »

BB&T announced a $5M…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Oct

GIS

General Mills

$44.99

-2.78 (-5.82%)

10:00
09/18/18
09/18
10:00
09/18/18
10:00
Technical Analysis
Technical Take: General Mills falls sharply after earnings »

The stock was last down…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 28

    Oct

BBY

Best Buy

$77.25

0.22 (0.29%)

10:00
09/18/18
09/18
10:00
09/18/18
10:00
Options
Notable short-term option spreads in Best Buy »

Notable short-term option…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ACBFF

Aurora Cannabis

$0.00

(0.00%)

09:58
09/18/18
09/18
09:58
09/18/18
09:58
Hot Stocks
Aurora Cannabis trading in Canada halted, pending news »

The Investment Industry…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

UNP

Union Pacific

$164.22

7.49 (4.78%)

09:58
09/18/18
09/18
09:58
09/18/18
09:58
Conference/Events
Union Pacific to hold a conference call »

Management discusses the…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 06

    Nov

UNP

Union Pacific

$164.03

7.3 (4.66%)

, FTI

TechnipFMC

$30.94

1.03 (3.44%)

09:55
09/18/18
09/18
09:55
09/18/18
09:55
Options
Early notable gainers among liquid option names on September 18th »

Notable gainers among…

UNP

Union Pacific

$164.03

7.3 (4.66%)

FTI

TechnipFMC

$30.94

1.03 (3.44%)

UHS

Universal Health

$131.36

5.33 (4.23%)

RIG

Transocean

$11.97

0.375 (3.23%)

HES

Hess Corp.

$68.20

1.41 (2.11%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 06

    Nov

09:55
09/18/18
09/18
09:55
09/18/18
09:55
General news
U.S. NAHB housing market index preview: »

U.S. NAHB housing market…

MBFI

MB Financial

$47.37

(0.00%)

, FITB

Fifth Third

$28.70

-0.01 (-0.03%)

09:50
09/18/18
09/18
09:50
09/18/18
09:50
Hot Stocks
MB Financial receives shareholder approval for merger with Fifth Third »

MB Financial (MBFI)…

MBFI

MB Financial

$47.37

(0.00%)

FITB

Fifth Third

$28.70

-0.01 (-0.03%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 23

    Oct

UNP

Union Pacific

$163.89

7.16 (4.57%)

09:49
09/18/18
09/18
09:49
09/18/18
09:49
Technical Analysis
Technical Take: Union Pacific moves to new high, analyst action »

The stock was last up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

FATE

Fate Therapeutics

$11.06

(0.00%)

09:49
09/18/18
09/18
09:49
09/18/18
09:49
Recommendations
Fate Therapeutics analyst commentary  »

Fate Therapeutics price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Oct

AZO

AutoZone

$717.00

-30.53 (-4.08%)

09:47
09/18/18
09/18
09:47
09/18/18
09:47
Hot Stocks
AutoZone falls -4.2% »

AutoZone is down -4.2%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 29

    Oct

BRC

Brady

$43.45

-1.9 (-4.19%)

09:47
09/18/18
09/18
09:47
09/18/18
09:47
Hot Stocks
Brady falls -3.8% »

Brady is down -3.8%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

WK

Workiva

$34.60

-3.2 (-8.47%)

09:47
09/18/18
09/18
09:47
09/18/18
09:47
Hot Stocks
Workiva falls -8.9% »

Workiva is down -8.9%, or…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Sep

  • 20

    Sep

SMG

Scotts Miracle-Gro

$79.42

0.45 (0.57%)

09:47
09/18/18
09/18
09:47
09/18/18
09:47
Conference/Events
Scotts Miracle-Gro management to meet with SunTrust »

Meetings to be held on…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

  • 19

    Sep

  • 20

    Sep

  • 21

    Sep

UNP

Union Pacific

$164.33

7.6 (4.85%)

09:47
09/18/18
09/18
09:47
09/18/18
09:47
Hot Stocks
Union Pacific rises 4.8% »

Union Pacific is up 4.8%,…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 06

    Nov

CRC

California Resources

$38.68

1.91 (5.19%)

09:47
09/18/18
09/18
09:47
09/18/18
09:47
Hot Stocks
California Resources rises 5.5% »

California Resources is…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Oct

THO

Thor Industries

$109.35

11.78 (12.07%)

09:47
09/18/18
09/18
09:47
09/18/18
09:47
Hot Stocks
Thor Industries rises 12.3% »

Thor Industries is up…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 18

    Sep

09:45
09/18/18
09/18
09:45
09/18/18
09:45
General news
Housing Market Index to be reported at 10:00 »

September Housing Market…

ATHN

Athenahealth

$143.26

(0.00%)

09:43
09/18/18
09/18
09:43
09/18/18
09:43
Periodicals
CNBC's Faber: Elliott may not have walked away from Athenahealth »

CNBC's David Faber…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ELF

e.l.f. Beauty

$13.41

(0.00%)

, AVP

Avon Products

$2.09

(0.00%)

09:40
09/18/18
09/18
09:40
09/18/18
09:40
Periodicals
Dealreporter speculates on interest in e.l.f. Beauty after report about Avon »

After The Wall Street…

ELF

e.l.f. Beauty

$13.41

(0.00%)

AVP

Avon Products

$2.09

(0.00%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 21

    Sep

  • 26

    Sep

  • 28

    Oct

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.